368 completed. 368 Phase 2, 79 Phase 1, 47 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 368 | Completed 368 |
| Phase 1 | 79 | Completed 79 |
| Phase 3 | 47 | Completed 47 |
Follow Vector Borne Diseases: new trials by email Literature Review of Vector Borne Diseases trials Research Report on Vector Borne Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1) KAE609 (Cipargamin), SoC (Coartem), INE963 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 95 | 2025-10-10 | 2026-09-10 |
| L9LS in Women of Childbearing Potential in Mali Single dose of 1800 mg L9LS SC, Placebo - Malaria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 279 | 2025-07-22 | 2026-10-30 |
| A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 161 | 2025-02-24 | 2026-09-11 |
| A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan TDV, Placebo - Dengue Fever | Phase 2 / Phase 3 | Completed | Takeda | 187 | 2025-01-31 | 2025-12-30 |
| A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection AV-1 100 mg, AV-1 300 mg, AV-1 900 mg - DENV-3 Controlled Human Infection Model | Phase 2 | Completed | AbViro LLC | 85 | 2025-01-07 | 2026-03-31 |
| Study to Examine the Effects of Oral Fenretinide ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo - Dengue | Phase 2 | Completed | Island Pharmaceuticals | 15 | 2024-09-05 | 2025-10-24 |
| Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali TB31F, Normal saline - Malaria,Falciparum | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 167 | 2024-07-12 | 2026-01-22 |
| Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients CPLE, Placebo - Dengue Fever | Phase 1 / Phase 2 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 184 | 2024-06-01 | 2025-04-25 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria INE963 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 52 | 2024-01-23 | 2025-11-19 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2) KAE609, SoC (Coartem), KLU156 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 60 | 2024-01-23 | 2026-05-07 |
| A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years VLA1553 full dose, VLA1553 half dose, Control - Chikungunya Virus Infection | Phase 2 | Completed | Valneva Austria GmbH | 304 | 2023-12-18 | 2026-08-13 |
| Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2) M5717 60 mg, Pyronaridine, Atovaquone-Proguanil - Malaria Infection | Phase 2 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 192 | 2023-11-28 | 2026-02-06 |
| A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria BNT165c, BNT165d, Placebo - Malaria | Phase 1 / Phase 2 | Completed | BioNTech SE | 163 | 2023-11-13 | 2026-08-28 |
| A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines RH5.1 and/or RH5.2-VLP with Matrix-M - Malaria, Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 41 | 2023-08-18 | 2026-07-20 |
| A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age mRNA-1975, mRNA-1982, Placebo - Lyme Disease | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 807 | 2023-07-26 | 2026-07-30 |
| L9LS MAb in Malian Adults L9LS (VRC-MALMAB0114-00-AB), Placebo - Plasmodium Falciparum Infection, Malaria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 490 | 2023-05-25 | 2025-04-02 |
| Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial Artemether-lumefantrine and Amodiaquine Drug Combination, Artemether-lumefantrine then Artesunate amodiaquine, Artemether-lumefantrine - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 / Phase 3 | Completed | Muhimbili University of Health and Allied Sciences | 384 | 2023-05-01 | 2026-09-23 |
| A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso. Rabies vaccine, RH5.1 10μg adjuvated with 50μg Matrix-M, RH5.2 5μg adjuvated with 50μg Matrix-M - Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 390 | 2023-04-03 | 2026-10-21 |
| Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1) M5717 330 mg, M5717 500 mg, M5717 660 mg - Acute Malaria | Phase 2 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 38 | 2023-03-29 | 2025-08-27 |
| Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002) V181, Butantan - DV - Dengue | Phase 2 | Completed | Butantan Institute | 1364 | 2023-02-15 | 2025-11-18 |
Showing 20 of 368. Sign in to see all of them.
Malaria (141) · Malaria, Falciparum (78) · Dengue (43) · Leishmaniasis, Cutaneous (28) · Severe Dengue (20) · Leishmaniasis (18) · Malaria, Vivax (17) · Encephalitis, Japanese (12) · Schistosomiasis (10) · Chikungunya Fever (8) · Encephalitis, Tick-Borne (8) · Lyme Disease (8) · Chagas Disease (7) · Leishmaniasis, Mucocutaneous (7) · Trypanosomiasis, African (7)
Infections (363) · Mosquito-Borne Diseases (268) · Parasitic Diseases (258) · Protozoan Infections (241) · RNA Virus Infections (84) · Arbovirus Infections (83) · Virus Diseases (83) · Flaviviridae Infections (70) · Flavivirus Infections (70) · Euglenozoa Infections (56) · Hemorrhagic Fevers, Viral (50) · Malaria (45) · Skin Diseases, Infectious (38) · Skin and Connective Tissue Diseases (38)
Artemether, Lumefantrine Drug Combination (18) · Primaquine (17) · Amodiaquine (14) · miltefosine (14) · Artesunate (13) · fanasil, pyrimethamine drug combination (13) · Chloroquine (12) · Azithromycin (9) · Ivermectin (9) · Saline Solution (9) · Sodium Chloride (9) · Vaccines (8) · Praziquantel (7) · RTS malaria vaccine (7) · Rabies Vaccines (7)
U.S. Army Medical Research and Development Command (36) · University of Oxford (32) · National Institute of Allergy and Infectious Diseases (NIAID) (21) · GlaxoSmithKline (20) · London School of Hygiene and Tropical Medicine (20) · Sanofi Pasteur, a Sanofi Company (17) · Pfizer (13) · Medicines for Malaria Venture (11) · Drugs for Neglected Diseases (10) · Novartis Pharmaceuticals (10) · Sanofi (9) · Heidelberg University (5) · Hospital Universitário Professor Edgard Santos (5) · Oswaldo Cruz Foundation (5) · Sanaria Inc. (5)
United States (63) · Mali (26) · Burkina Faso (25) · Kenya (23) · Thailand (23) · Brazil (21) · United Kingdom (21) · Uganda (18) · Gabon (17) · Colombia (15) · India (13) · Ghana (11) · Democratic Republic of the Congo (10) · Vietnam (10) · Mozambique (9)
Adrian VS Hill, D.Phil, FRCP (4) · Kassoum Kayentao, MD, MPH, PhD (4) · Adrian V S Hill, MD (3) · Brian Greenwood, FRCP, FRS (3) · James McCarthy, Prof (3) · Peter Crompton, MD, MPH (3) · Adrian V Hill, DPhill FRCP (2)
PMID 39377226, PMID 40099800, PMID 28495354, PMID 19150418, PMID 2022660, PMID 21298114, PMID 21443960, PMID 23284726, PMID 23433102, PMID 23877689, PMID 23899517, PMID 23962071, PMID 25211344, PMID 26292027, PMID 26292257, PMID 26571311, PMID 26881924, PMID 27695088, PMID 31672143, PMID 32932330, PMID 33998661, PMID 35664997, PMID 36875126, PMID 38830375, PMID 41176969, PMID 10190913, PMID 10501745, PMID 12011004, PMID 12663340, PMID 15069048, PMID 16269927, PMID 16338450, PMID 16503464, PMID 16837678, PMID 16904798, PMID 17442466, PMID 17707447, PMID 18231580, PMID 18270560, PMID 18286187, PMID 18320064, PMID 18337339, PMID 18545693, PMID 18694333, PMID 18752443, PMID 18781879, PMID 19098989, PMID 19262754, PMID 19365567, PMID 19390585
2014 (5), 2016 (4), 2015 (3), 2018 (2), R01NS074409 (2), R01HD095562 (1), R01HL086488 (1), R01NS102176 (1), U01AI065683 (1), U01AI129783 (1), U01AI141981 (1)